Orphazyme A/S Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2009

Location

Copenhagen Denmark

Primary Industry

Biotechnology

About

Based in Herlev, Denmark, and founded in 2009, Orphazyme A/S operates as a biotechnology company that develops therapies for the treatment of lysosomal storage and protein misfolding diseases such as Inclusion Body Myositis (sIBM), Amyotrophic Lateral Sclerosis (ALS), Niemann Pick Type C (NPC), and Gaucher. The firm was listed on Nasdaq Copenhagen in 2017 and is trading under the ticker symbol, ORPHA. In November 2017, Orphazyme raised EUR 80 million in PIPE funding led by investors Kuma Partners, Sunstone Life Science Ventures, Life Sciences Partners, etc. Further, in May 2022, the business was acquired by KemPharm for USD 12.8 million in cash and USD 5.2 million in liabilities. The firm as of January 2024, is led by its CEO, Jakob Bendtsen.

Current Investors

Heartcore Capital, Novo Holdings, Novo Holdings

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy

Website

www.orphazyme.com

Company Stage

Acquired

Total Amount Raised

Subscriber access only

Financials

Fiscal Year Ended
Revenue (USD)
% Revenue Growth (YoY)
Operating Income (USD)
Operating Margin
EBITDA (USD)
% EBITDA Margin
NET Income (USD)
% Net Margin

30 Jun 2010

(571,181)

(446,181)

(574,404)

30 Jun 2011

(10,016,788)

(10,012,734)

30 Jun 2012

(18,560,145)

(18,543,344)

(16,786,721)

30 Jun 2013

(36,959,113)

(36,786,457)

(35,763,084)

30 Jun 2014

(37,717,491)

(37,211,028)

(31,468,197)

30 Jun 2015

(37,102,460)

(36,598,677)

(31,958,124)

31 Dec 2016

(63,520,000)

(62,814,000)

(57,935,000)

31 Dec 2017

(131,042,000)

(130,415,000)

(126,204,000)

31 Dec 2018

(231,652,000)

(230,286,000)

(229,600,000)

31 Dec 2019

(335,954,000)

(332,151,000)

(337,497,000)

31 Dec 2020

(608,534,000)

(603,334,000)

(633,246,000)

31 Dec 2021

31 Dec 2022

31 Dec 2023

Unlock the recent years of financials and more for Orphazyme A/S.

Request a demo to see more.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.